𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐂𝐋𝐋 𝐝𝐮𝐫𝐢𝐧𝐠 𝐚𝐜𝐭𝐢𝐯𝐞 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠: 𝐚 𝐜𝐚𝐥𝐥-𝐭𝐨-𝐚𝐜𝐭𝐢𝐨𝐧 For patients diagnosed with 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐋𝐲𝐦𝐩𝐡𝐨𝐜𝐲𝐭𝐢𝐜 𝐋𝐞𝐮𝐤𝐞𝐦𝐢𝐚 (CLL), ‘𝐚𝐜𝐭𝐢𝐯𝐞 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠’, also referred to as ‘𝐰𝐚𝐭𝐜𝐡 𝐚𝐧𝐝 𝐰𝐚𝐢𝐭’ or ‘𝐚𝐜𝐭𝐢𝐯𝐞 𝐬𝐮𝐫𝐯𝐞𝐢𝐥𝐥𝐚𝐧𝐜𝐞’ is not only a treatment approach, but also a complex period from an emotional and psychological point of view. To address the significant challenges that patients with CLL and their care partners face during active monitoring, we call on all those who can make a difference – including healthcare providers, patient organisations, policymakers, medical societies and industry – to join forces and drive for change. There are 𝐭𝐡𝐫𝐞𝐞 𝐟𝐨𝐜𝐮𝐬 𝐚𝐫𝐞𝐚𝐬 needing immediate action: 👉 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐫 (𝐇𝐂𝐏)𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧 👉 𝐈𝐦𝐩𝐫𝐨𝐯𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐫𝐮𝐬𝐭𝐰𝐨𝐫𝐭𝐡𝐲 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 👉 𝐒𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧 𝐩𝐞𝐞𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐨𝐫𝐠𝐚𝐧𝐢𝐬𝐚𝐭𝐢𝐨𝐧 𝐞𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 CTA Report Link: https://lnkd.in/g-urBqvp #NavigatingCLLTogether #CLL #BeOneAgainstCancer

At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Elizabeth Wulff-Burchfield, Associate Professor and Medical Oncologist at the University of Kansas Health System, delivered a talk on “Palliative Care Integration in Advanced RCC”. She emphasized that palliative care is not limited to end-of-life support, but an essential component of high-quality cancer care from the time of diagnosis. By focusing on symptom relief, psychosocial support, and shared decision-making, palliative care helps patients with renal cell carcinoma navigate the complexities of modern treatment while maintaining quality of life. Dr. Wulff-Burchfield highlighted the importance of distinguishing between primary and specialty palliative care, noting the need for every oncologist to adopt core communication skills such as addressing goals of care, discussing tolerance for medical burden, and cultivating prognostic awareness. Join us in this conversation: https://lnkd.in/evR3M4hi https://lnkd.in/eyh-bTqf #OncoDaily #Oncology #Cancer #Health #Medicine #VIRO #VIRO2025

Starting cancer treatment brings many unknowns, but understanding how chemotherapy affects your blood counts is crucial for safe, informed care. In our latest #SanguinaBlog, we break down: 🔬 How different chemotherapy drugs impact bone marrow production 🩺 The three critical blood cell types and what happens when counts drop ⚠️ Warning signs of neutropenia and when to contact your medical team immediately 💪 Recovery timelines and supportive treatments available For patients, caregivers, and healthcare professionals, this comprehensive guide transforms complex medical information into empowering knowledge for navigating cancer treatment safely. 📖 Read the complete patient guide →http://bit.ly/3VM1jFj #SanguinaBlog #ChemotherapyEducation #CancerCare #PatientAdvocacy #BloodHealthMatters #Sanguina

GOOD NEWS: Pharmac has secured savings by negotiating better deals with medicine suppliers and can now fund five new treatments for multiple sclerosis, breast cancer, lung cancer, and eye conditions. These treatments are faster to administer, saving thousands of hospital hours and freeing up health professionals to deliver more care. This is what a strong focus on fixing what matters delivers. Clinicians, the public, and patient advocates will be consulted to ensure New Zealanders have access to timely, quality healthcare.

For Chronic Lymphocytic Leukemia (CLL) patients, the phrase 'watch and wait' can create anxiety and uncertainty during active monitoring. To dispel this anxiety, this #BloodCancerAwarenessMonth we are committed to ensuring patients with CLL and their carers have access to clear and credible information. Collaborating with our panel of experts, including leading healthcare professionals, CLL patients and advocates, Jan Geissler, Christina Karamanidou, Jana Pelouchova, Lydia Scarfo and Peter Haggert, we are working to address the pressing challenges faced by those living with CLL. As leading contributors to the CLL Call-To-Action Report, the panel explored key areas of unmet need, and innovative approaches to care, emphasizing the emotional and practical support required to navigate active monitoring. Watch the full discussion to hear about how you can take actionable steps to improve the lives of people living with CLL: https://lnkd.in/gcSWTd2R #NavigatingCLLTogether #BeOneAgainstCancer #CLL, #BloodCancerAwarenessMonth

Bridging gaps between clinicians, patient organisations, and patient communities is crucial. As a former clinician, I witnessed how a cohesive line of communication between professionals and patients, not only ensures that patients gain deeper insights into their conditions but significantly improves their health literacy. When patient voices are heard and translated into meaningful action, we set the stage for groundbreaking advancements in healthcare delivery. We need every voice in the room to be heard—patients, clinicians, researchers, and advocates—to make true progress. Our teams kept this at the heart of their efforts when bringing multidisciplinary stakeholders together to create the CLL Active Monitoring Call-to-Action Report and again, for the active monitoring panel discussion. Each patient's journey is uniquely shaped by diverse circumstances and backgrounds— there is no universal patient experience. Our work must support and reflect this reality; we must tailor our approach to empower patients; we must continue to champion the importance of inclusivity and personalisation in care.  During Blood Cancer Awareness Month, I urge you to learn about the nuances of patient experiences, and share what inspires you with others, engage in dialogues that lead to meaningful change and advocate for inclusive practices within your spheres of influence. Imagine a future where healthcare is not a one-size-fits-all model, but a dynamic, responsive system that adapts to the needs of each individual. Together, let's shape a healthcare landscape where every patient feels seen, heard, and empowered to steer their health journey with confidence and clarity. 

Morning administration of anthracyclines cuts cardiotoxicity risk A new study in European Heart Journal Open shows that when chemotherapy is given matters as much as what is given. Key findings (270 patients treated with anthracyclines): - Morning administration = safer for the heart - Afternoon administration → ~3× higher risk of cardiotoxicity - Every +10% of infusions in the afternoon increases: => Risk of cardiac dysfunction by +14% => Risk of heart failure by +19% Take-home message: scheduling anthracyclines in the morning could significantly reduce the risk of cardiac damage in cancer patients. Read the full study here: European Heart Journal Open – Morning administration of anthracyclines https://lnkd.in/eTTxWCVc Authors: Markella I. Printezi, Arco J. Teske, Nicolaas P. A. Zuithoff, Kim Urgel, Rhodé M. Bijlsma, Anna van Rhenen, Maarten Jan Cramer, Cornelis J. A. Punt, Anne M. May, Linda W. van Laake. #CardioOncology #Chronotherapy #CircadianRhythms #CancerResearch #HeartHealth #Anthracyclines #Oncology #CardioOnc #MedicalResearch #InnovationInMedicine #PatientCare #ClinicalOncology #circamed

Takeda September 15 marked #WorldLymphomaAwarenessDay — a moment to raise awareness not just for lymphoma itself but for key challenges patients face along their treatment journey. One of those challenges is secondary immunodeficiency (SID), when the immune system is weakened by another illness or treatment. Prompt diagnosis and collaborative care can help minimize health risks and improve outcomes. 👏 Kudos to patient advocacy groups like CLL Advocates Network for equipping patients with resources to take an active role in care decisions. How do you foster shared decision-making in your work with patients or research? #CLL #PatientAdvocacy #HealthDecisions

Throwback to a Key 2024 Study on Long-Term Survival Prediction in HCC Looking back at this important 2024 publication led by David Goldberg, which developed a purely objective risk score to predict 5-year survival in patients with early- to intermediate-stage hepatocellular carcinoma (HCC). Using data from over 1,300 patients in the Veterans Health Administration, this model showed excellent discrimination (AUC: 0.71) and outperformed standard staging systems like BCLC and ALBI. This work remains highly relevant today, offering a valuable tool for guiding treatment strategies and assessing the net survival benefit of liver transplantation compared with other curative options — a step toward more personalized care for HCC patients. Kudos to David Goldberg and all co-authors for this lasting contribution to the field. Read more:https://lnkd.in/eMFUy_fG #OncologyFrontier #HCC #LiverCancer #HCCResearch #PrecisionMedicine #CancerResearch #Transplantation #OncologyUpdates #SurvivalPrediction

At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Regina Barragán, Postdoctoral Fellow at the Genitourinary Clinic, City of Hope, spoke on “The Current State of Renal Oncology in Mexico.” She emphasized the rising incidence and mortality of RCC, regional inequities in access to care, and the challenges of a fragmented health system. Dr. Barragán highlighted the lack of robust registries, limited clinical trial opportunities, and disparities between public and private treatment settings. Join us in this conversation: https://lnkd.in/eKACugjw https://lnkd.in/e-d3PrgA #OncoDaily #Oncology #Cancer #Health #Medicine